• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24094 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2017     Agency for Care Effectiveness (ACE) Somatropin for the treatment of growth failure in children
2000     Alberta Heritage Foundation for Medical Research (AHFMR) Somnoplasty (R) system
2015     NIHR Horizon Scanning Centre (NIHR HSC) Sonata™ System for the removal of uterine fibroids
2005     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Sonographic diagnosis of acute abdomen in children and adults
2015     HAYES, Inc. Sonohysterography for assessment of abnormal uterine bleeding
2005     Adelaide Health Technology Assessment (AHTA) SonoPrep (R) Ultrasonic Skin Permeation system for skin preparation prior to cutaneous penetration
2005     New Zealand Health Technology Assessment (NZHTA) SonoPrep ultrasonic skin permeation system
2012     National Institute for Health and Care Excellence (NICE) SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver. NICE diagnostics guidance 5
2007     NIHR Horizon Scanning Centre (NIHR HSC) Sorafenib (Nexavar) for advanced non-small cell lung cancer
2011     NIHR Horizon Scanning Centre (NIHR HSC) Sorafenib (Nexavar) for hepatocellular carcinoma - adjuvant therapy
2007     NIHR Horizon Scanning Centre (NIHR HSC) Sorafenib (Nexavar) for hepatocellular carcinoma: horizon scanning technology briefing
2011     NIHR Horizon Scanning Centre (NIHR HSC) Sorafenib (Nexavar) in combination with capecitabine for HER2-negative locally advanced or metastatic breast cancer - second line
2016     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Sorafenib (Nexavar®)
2006     NIHR Horizon Scanning Centre (NIHR HSC) Sorafenib for advanced hepatocellular carcinoma (HCC): horizon scanning review
2010     NIHR Health Technology Assessment programme Sorafenib for the treatment of advanced hepatocellular carcinoma
2017     National Institute for Health and Care Excellence (NICE) Sorafenib for treating advanced hepatocellular carcinoma. NICE technology appraisal guidance 474
2006     NIHR Horizon Scanning Centre (NIHR HSC) Sorafenib tosylate (nexavar) for advanced renal cell carcinoma: horizon scanning review
2019     European Network for Health Technology Assessment (EUnetHTA) Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy
2020     National Institute for Health and Care Excellence (NICE) Sotagliflozin with insulin for treating type 1 diabetes. NICE technology appraisal guidance 622
2024     Institute for Clinical and Economic Review (ICER) Sotatercept for pulmonary arterial hypertension
2022     National Institute for Health and Care Excellence (NICE) Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 781
2011     NIHR Horizon Scanning Centre (NIHR HSC) Soundbite hearing system
2014     HAYES, Inc. SoundBite hearing system (Sonitus Medical Inc.) for treatment of unilateral hearing loss
2023     Agency for Care Effectiveness (ACE) SpaceOAR systems for rectum protection during prostate cancer treatment
2014     NIHR Horizon Scanning Centre (NIHR HSC) SpaceOAR® perirectal spacing system for prostate cancer radiation
2025     National Institute for Health and Care Excellence (NICE) Sparsentan for treating primary IgA nephropathy. NICE technology appraisal guidance 1074
2012     NIHR Horizon Scanning Centre (NIHR HSC) Spartan RX™ point-of-care DNA test for identifying the CYP2C19*2 mutation
2022     Institute for Clinical and Economic Review (ICER) Special assessment of outpatient treatments for COVID-19
1992     U. S. Congress. Office of Technology Assessment (OTA) Special care units for people with Alzheimer's and other dementias: consumer education, research, regulatory and reimbursement issues
2008     Blue Cross Blue Shield Association (BCBS) Special report: aCGH for the genetic evaluation of patients with developmental delay/mental retardation or autism spectrum disorder
2007     Blue Cross Blue Shield Association (BCBS) Special report: cardiovascular pharmacogenomics
2015     Blue Cross Blue Shield Association (BCBS) Special report: chromosomal microarray for the genetic evaluation of patients with global developmental delay, intellectual disability, and autism spectrum disorder
2012     Blue Cross Blue Shield Association (BCBS) Special report: chronic noncancer pain—long-term opioid benefits and harms
2011     Blue Cross Blue Shield Association (BCBS) Special report: companion diagnostics: example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors
2009     Blue Cross Blue Shield Association (BCBS) Special report: critical appraisal of CT colonography cost-effectiveness analyses
2005     Blue Cross Blue Shield Association (BCBS) Special report: current and evolving strategies in the treatment of age-related macular degeneration
2015     Blue Cross Blue Shield Association (BCBS) Special report: early intensive behavioral intervention and other behavioral interventions for autism spectrum disorder
2008     Blue Cross Blue Shield Association (BCBS) Special report: early intensive behavioral intervention based on applied behavior analysis among children with autism spectrum disorders
2003     Blue Cross Blue Shield Association (BCBS) Special report: Evidence on sequencing of conventional and biological disease-modifying anti-rheumatic drugs
2013     Blue Cross Blue Shield Association (BCBS) Special Report: exome sequencing for clinical diagnosis of patients with suspected genetic disorders
2006     Blue Cross Blue Shield Association (BCBS) Special report: fecal DNA analysis for colon cancer screening
2004     Blue Cross Blue Shield Association (BCBS) Special Report: Genotyping for cytochrome p450 polymorphisms to determine drug-metabolizer status
2003     Blue Cross Blue Shield Association (BCBS) Special report: high-sensitivity C-reactive protein measurement for coronary heart disease risk stratification
2006     Blue Cross Blue Shield Association (BCBS) Special report: intensity-modulated radiation therapy for cancer of the breast or lung
2003     Blue Cross Blue Shield Association (BCBS) Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders
2005     Blue Cross Blue Shield Association (BCBS) Special report: intra-articular hyaluronan for osteoarthritis of the knee
2009     Blue Cross Blue Shield Association (BCBS) Special report: laboratory testing to allow area under the curve (AUC) - targeted 5-Fluorouracil dosing for patients administered chemotherapy for cancer
2011     Blue Cross Blue Shield Association (BCBS) Special report: maintenance therapy in advanced non-small-cell lung cancer
2006     Blue Cross Blue Shield Association (BCBS) Special report: measuring and reporting pain outcomes in randomized controlled trials
2014     Blue Cross Blue Shield Association (BCBS) Special report: medication adherence
2008     Blue Cross Blue Shield Association (BCBS) Special report: MEG and MSI for the purpose of presurgical localization of epileptic lesions - a challenge for technology evaluation
2013     Blue Cross Blue Shield Association (BCBS) Special Report: multiple molecular testing of cancers to identify targeted therapies
2007     Blue Cross Blue Shield Association (BCBS) Special report: pharmacogenomics of cancer-candidate genes
2010     Blue Cross Blue Shield Association (BCBS) Special report: positron emission tomography for the indication of post-treatment surveillance of cancer
2008     Blue Cross Blue Shield Association (BCBS) Special report: recent developments in prostate cancer genetics and genetic testing
2006     Blue Cross Blue Shield Association (BCBS) Special report: recombinant activated factor VII for uncontrolled bleeding in non-hemophiliac patients
2014     Blue Cross Blue Shield Association (BCBS) Special report: screening asymptomatic women with dense breasts and normal mammograms for breast cancer
2007     Blue Cross Blue Shield Association (BCBS) Special report: The efficacy and safety of statins in the elderly
2004     Blue Cross Blue Shield Association (BCBS) Special Report: The efficacy of interventions to change physician prescribing behavior
2004     Blue Cross Blue Shield Association (BCBS) Special Report: The publication of new evidence and effect on physician prescribing behaviors
2003     Blue Cross Blue Shield Association (BCBS) Special report: the relationship between weight loss and changes in morbidity following bariatric surgery for morbid obesity
2012     Blue Cross Blue Shield Association (BCBS) Special report: treatments for castration-resistant metastatic prostate cancer
2001     Blue Cross Blue Shield Association (BCBS) Special report: vaccines for the treatment of malignant melanoma
2009     Blue Cross Blue Shield Association (BCBS) Special report: vaccines for the treatment of prostate cancer
2006     Blue Cross Blue Shield Association (BCBS) Special report: wireless esophageal pH monitoring
2014     Medical Services Advisory Committee (MSAC) Specialist dermatology services delivered by asynchronous store and forward technology
2014     NIHR Health Services and Delivery Research programme Specialist rehabilitation for people with Parkinson's disease in the community: a randomised controlled trial
2012     Medical Advisory Secretariat (MAS) Specialized community-based care: an evidence-based analysis
2013     Penn Medicine Center for Evidence-based Practice (CEP) Specialized geriatric care for hospitalized inpatients
2009     Medical Advisory Secretariat (MAS) Specialized multidisciplinary community-based care series: summary of evidence-based analyses
2012     Penn Medicine Center for Evidence-based Practice (CEP) Specialized neurocritical care units for traumatic brain injury
2013     Health Quality Ontario (HQO) Specialized nursing practice for chronic disease management in the primary-care setting: an evidence-based analysis
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Specialty mattresses for the prevention and management of pressure ulcers: a review of the clinical effectiveness, cost-effectiveness, and guidelines
1999     Hannover Medical School, Medizinische Hochschule Hannover (MHH) Specific desensitization with allergenic extracts for extrinsic asthma and allergy of insect poison
1999     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Specific desensitization with allergenic extracts for extrinsic asthma and allergy of insect poison - systematic review
2024     NIHR Health Technology Assessment programme Specific phobias in children with moderate to severe intellectual disabilities: SPIRIT, an adaptation and feasibility study
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Specifications of endosseous dental implants: a review of the advantages, disadvantages, and success rates
2004     Institute for Clinical Effectiveness and Health Policy (IECS) SPECT for the diagnosis and assessment of dementia and Alzheimer's disease
2016     National Institute for Health and Care Excellence (NICE) Spectra Optia for automatic red blood cell exchange in people with sickle cell disease. NICE medical technologies guidance 28
2000     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Spectral cytogenetic chromosome analyser - systematic review, primary research, expert panel
1998     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Spectral cytogenetic chromosome analyser (Spectracube SD 200) (systematic review, primary research, expert panel)
2013     NIHR Horizon Scanning Centre (NIHR HSC) Spectropath Image-Guided Surgery System with Spectropen™ for cancer surgery
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Speech and language therapy for children of preschool age: a review of the clinical-effectiveness and quality of life
2008     HAYES, Inc. Speech therapy for pervasive developmental disorders
2016     HAYES, Inc. Speech therapy for treatment of adults with primary progressive aphasia
2008     HAYES, Inc. Speech-generating devices for treatment of dysarthria
2009     HAYES, Inc. SpeechEasy (Janus Development Group Inc.) for treatment of stuttering
2007     NIHR Horizon Scanning Centre (NIHR HSC) SpeechEasy altered auditory feedback device for stammer
2004     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Sperm-washing in HIV-serodiscordant couples for use in assisted reproduction techniques
2025     National Institute for Health and Care Excellence (NICE) Spesolimab for treating generalised pustular psoriasis flares. NICE technology appraisal guidance 1070
2014     NIHR Horizon Scanning Centre (NIHR HSC) Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects
2012     HAYES, Inc. Sphincter pharyngoplasty for velopharyngeal insufficiency in children
2010     HAYES, Inc. Spinal and Bulbar Muscular Atrophy (SBMA; Kennedy Disease)
2006     HAYES, Inc. Spinal applications for stereotactic surgery
1996     Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) Spinal cord stimulation
2001     Wessex Institute for Health Research and Development (WIHRD) Spinal cord stimulation for chronic pain
2009     NIHR Health Technology Assessment programme Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation
2009     NIHR Health Technology Assessment programme Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation
2008     National Institute for Health and Care Excellence (NICE) Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin. NICE technology appraisal guidance 159
2005     Medical Advisory Secretariat (MAS) Spinal cord stimulation for neuropathic pain: an evidence-based analysis